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Fractionated stereotactic photon beam
radiotherapy
Side effects
Local tumour controla b s t r a c t
Purpose: To compare the adverse side effects of fractionated stereotactic photon beam radiotherapy
(fSRT) with proton beam radiotherapy (PBR) in patients with uveal melanoma (UM).
Methods: A retrospective study investigating 306 UM patients treated with fSRT (N=153) by the
Rotterdam Ocular Melanoma Study group (ROMS), The Netherlands, between 1999–2014 or with PBR
(N=153) at the Royal Liverpool University Hospital and the Clatterbridge Cancer Centre, Bebington,
United Kingdom, between 1993–2014. The tumours treated with fSRT were matched with tumours trea-
ted with PBR based on sex, left or right eye, TNM classification, posterior margin  or > 3mm of the fovea
and of the optic disc.
Results: The five-year actuarial rates of tumour recurrence were 4.5% for fSRT and 6.1% for PBR. For fSRT
and PBR, the five-year actuarial rates of maculopathy were 14.9% and 12.4%, and for vitreous haemor-
rhage were 29.4% and 4.7%, respectively. Only vitreous haemorrhage (HR: 0.19, 95% CI: 0.07–0.56) was
more common after fSRT compared to PBR. Overall, larger tumours were risk factors for maculopathy
and secondary enucleation.
Conclusions: Both treatments have excellent local tumour control. In matched groups, vitreous haemor-
rhage was the only adverse side effect showing a significant difference between groups.
 2021 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 157 (2021) 219–224 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Fractionated stereotactic photon beam radiotherapy (fSRT) and
proton beam radiotherapy (PBR) are both eye-sparing forms of
radiotherapy to treat uveal melanoma (UM). These therapeutic
modalities provide excellent tumour-control while conserving
the eye, usually with useful vision [1–3]. Several studies have con-
cluded that radiotherapy is as effective as enucleation concerning
metastatic disease and death [4,5]. Therefore, enucleation is now
reserved for eyes with a tumour deemed too large for radiotherapy
[6].
FSRT is suitable for small- and medium-sized melanomas up to
approximately 12 mm in thickness and a diameter less than16 mm. An advantage of fSRT over PBR is that it does not require
surgical insertion of fiducial markers for tumour localization and
that it is more readily available than PBR. Reported complications
of fSRT are neovascular glaucoma, cataract, vitreous haemorrhage,
optic neuropathy, maculopathy, retinopathy, and secondary enu-
cleation is required in 3–16% patients [1,7–9]. Local tumour control
rates have been reported as high as 96–100% after fSRT [1,7,8,10].
PBR is available in a growing number of centres in Europe. Some
ocular oncologists administer this treatment to all patients, while
others reserve it for patients whose tumour is considered unsuit-
able for brachytherapy. With PBR, radiation is delivered homoge-
nously to the tumour with the dose rapidly falling to zero distal
to the tumour [11]. PBR is generally reserved for tumours not
exceeding 20 mm in diameter and/or 12 mm in thickness, so as
to avoid severe exudative and neovascular complications resulting
in a blind and painful eye (‘toxic tumour syndrome’) [12]. The
reported local tumour control rates are 96% at 5 years and 94–
95% at 10 years after PBR [13–15]. Secondary enucleation rates
Side effects of fSRT versus PBR in uveal melanomaare 5–16% due to local recurrence or toxic tumour syndrome
[14,16,17]. Ocular morbidity can also occur as a result of collateral
damage to lens, optic nerve, macula and development of glaucoma
or vitreous haemorrhage [15,18].
Although, outcomes of fSRT and PBR for UM have been evalu-
ated, fSRT and PBR have not previously been compared with
respect to ocular outcomes of matched data in a large study popu-
lation [19]. As treatment indications, tumour control rates and
adverse side effects overlap between fSRT and PBR, we conducted
a retrospective study to compare fSRT with PBR for UM with
respect to local tumour control and ocular morbidity.Materials and methods
A retrospective study was conducted in 163 patients with chor-
oidal and/or ciliary body UM treated with fSRT by the Rotterdam
Ocular Melanoma Study group (ROMS), The Netherlands, between
December 1999 and January 2014, and 912 patients treated with
PBR in the Royal Liverpool University Hospital, United Kingdom,
between January 1993 and January 2014 in Liverpool. In order to
assess the differences in survival and to study the complications
between two treatments (fSRT and PBR) for UM, we matched both
cohorts of each 153 patients. The local medical ethical committees
of both institutes approved the study protocol. Informed consent
was obtained prior to treatment and the study was performed
according to guidelines of the Declaration of Helsinki.
Patients were diagnosed with UM by ophthalmic examination
and underwent full systemic examination. The fSRT patient data
were collected in a customised database application based on File-
maker 16 (FileMaker Inc, Santa Clara, California, United States). All
clinical data and follow-up data were collected for PBR and fSRT
patients. UM were categorised according to the TNM classification,
8th edition [20]. This classification is the same as the 8th edition of
the AJCC Classification of posterior uveal melanoma, T category
[21]. The following adverse outcomes were documented: local
recurrence, neovascular glaucoma, vitreous haemorrhage, optic
neuropathy, maculopathy and enucleation. Neovascular glaucoma
presented with open or closed angle, depending on the extent of
neovascularization. Optic neuropathy was defined as visual loss
caused by collateral optic nerve damage and diminished colour
vision (tested with Ishihara plates) with or without an afferent
pupillary defect. Maculopathy was diagnosed by the presence of
haemorrhages, hard exudates, and (non)-cystoid edema, which
was identified by ophthalmoscopy, optical coherence tomography
or fluorescein angiography when available. We excluded cystoid
macula edema developing after cataract extraction. Local recur-
rence of UM was determined clinically with or without ultrasonog-
raphy and by sequential fundus photography.
The fSRT and PBR protocols have been described previously
[1,3]. The stereotactic radiation dose is given in 5 fractions of 10
Gray (total 50 Gray), at the 80% isodose over five consecutive days
and the proton radiation dose is 53 proton Gray in 4, daily
fractions.Statistical analyses
Matching was based on the following variables: age, sex, TNM-
classification, tumour distances to the fovea and optic disc. For age
we applied a window of 5 years, however the other variables
required an exact match. As a consequence, 10 of the 163 patients
treated with fSRT could not be matched and were excluded; this
resulted in 153 fSRT and 153 PBR patients. Differences in complica-
tions (i.e., after treatment) between patients treated with fSRT and
PBR were analysed using independent t-tests and Chi-square
statistics.220The risk of a complication caused by a tumour characteristic
was analysed by applying Cox proportional hazard models in the
unmatched complete dataset to calculate hazard ratios (HR) with
corresponding 95% confidence intervals (CI). Follow-up duration,
used as the time variable, was measured from the date of treat-
ment to the latest visit. The models were adjusted for age, sex,
and often for type of treatment (i.e., fSRT or PBR). The risk of a com-
plication caused by treatment (fSRT of PBR) was analysed in a
matched dataset [N = 306] by applying ‘‘non-conditional” and con-
ditional Cox proportional hazard models. Follow-up duration was
used as the time variable.
Cumulative incidence analyses were performed on the matched
dataset and the log-rank test was used to assess statistical signifi-
cance between the curves. Actuarial rates were calculated at 1, 3, 5,
and 10 years of follow-up. We used complete case analysis and
considered p-value  0.05 as statistically significant. All statistical
analyses were performed using IBM SPSS Statistics version 22.0 for
Windows (SPSS inc., Chicago, IL, USA) and R statistical package ver-
sion 3.6.1 for Mac (http://www.r-project.org).Results
Our study cohort included, 153 UM patients of whom were
treated with fSRT and 153 with PBR (Table 1). The two treatment
groups were matched, based on the significant differences in
tumour characteristics between the fSRT and PBR group.
The median follow-up times of the fSRT and PBR groups were
58.5 months (IQR: 26.1–95.2 months) and 40.0 months (IQR:
19.1–70.0 months) respectively (p < 0.001). The 5-year local
tumour control rates were 96.1% for fSRT and 96.1% for PBR. At
the end of the study, the local tumour control was 94.1% after fSRT
with 15 years of follow-up and 95.4% after PBR with 15 years (and
20 years) of follow-up, respectively (p = 0.798; Table 1). The actu-
arial rates of tumour recurrence are presented in Table 2. The med-
ian interval between fSRT and tumour recurrence (N = 9) was
19.8 months (IQR: 14.0–72.7 months). The median interval
between PBR and tumour recurrence (N = 7) was 29.4 months
(IQR: 15.3–36.7 months). Three tumours treated with fSRT devel-
oped a recurrence after more than five years (i.e., after 5.3, 6.8
and 7.0 years). These were T3, T2 and T1 class tumours of the
TNM classification respectively. One T1 tumour treated with PBR
developed a recurrence after more than five years (i.e., after
9.2 years). However, greater tumour size and tumour location
(3 mm to the fovea and  3 mm to the optic disc) were not asso-
ciated with a higher incidence of tumour recurrences irrespective
of treatment (Table 3). Furthermore, local tumour recurrence was
not significant associated with a type of treatment (Table 4). Sec-
ondary enucleation for tumour recurrence was performed in 8
(5.3%) patients after fSRT and 3 (2.0%) after PBR. One fSRT patient
with a tumour recurrence received additional fSRT. Four PBR
patients with tumour recurrence received additional treatment,
such as trans pupillary thermotherapy, iodine plaque radiotherapy,
ruthenium plaque radiotherapy or adjunctive PBR. The 5-year enu-
cleation rate is higher in patients treated with fSRT (12.4%) than in
patients treated with PBR (5.9%). Multivariate analyses showed in
the study population (N = 306) that the incidence of vitreous
haemorrhages (VH) was significantly higher after fSRT than PBR
(HR: 0.19; 95% CI 0.07–0.56) (p < 0.0001) (Table 4 and Fig. 1).
Fig. 1 shows the cumulative incidence of all complications and
complications during follow-up.
Regardless of treatment, neovascular glaucoma was 2.0 times
significantly more common in tumours that were further than
3 mm of the fovea (Table 3). The rate of neovascular glaucoma
was higher in fSRT patients (17.6%) than in PBR patients (8.5%)
(p = 0.027). The median time to develop neovascular glaucoma
Table 3
The risk of a complication caused by a tumour characteristic in the study population
(N = 306). Presented as hazard ratio with corresponding 95% CI*.
Reference
level
TNM-classification 1 Margin to the
fovea  3 mm
Margin to the optic
disc  3 mm
Recurrence 1.69 (0.81–3.51) 1.36 (0.50–3.70) 2.46 (0.77–7.88)
Neovascular
glaucoma
1.50 (1.00–2.34) 2.04 (1.07–3.90)# 1.40 (0.72–2.70)
Vitreous
haemorrhage
0.94 (0.62–1.41) 0.93 (0.48–1.78) 0.83 (0.43–1.59)
Optic neuropathy 1.31 (0.77–2.23) 0.72 (0.31–1.68) 0.24 (0.09–0.62)#
Maculopathy 1.99 (1.21–3.26)# 0.96 (0.48–1.91) 1.52 (0.75–3.09)
Enucleation 1.91 (1.14–3.22)# 1.00 (0.50–2.01) 1.20 (0.59–2.44)
CI = confidence interval.
* = adjusted for age and gender.
# = Significant values.
Table 1
General characteristics of the study population and complications after treatment







Age (mean ± SD) in years 61.8 ± 11.1 61.6 ± 10.6
Female (N [%]) 72 (47.1) 72 (47.1)
Tumour characteristics
TNM class (N [%])
1 34 (22.2) 34 (22.2)
2 64 (41.8) 64 (41.8)
3 55 (35.9) 55 (35.9)
4 0 (0.0) 0 (0.0)
Margin to the fovea  3 mm (N [%]) 88 (57.5) 88 (57.5)
Margin to the optic disc  3 mm (N
[%])
77 (50.3) 77 (50.3)
Complications
Recurrence (N [%]) 9 (5.9) 7 (4.6) 0.798
Neovascular glaucoma (N [%]) 27 (17.6) 13 (8.5) 0.027
Vitreous haemorrhage (N [%]) 28 (18.3) 5 (3.3) <0.001
Optic neuropathy (N [%]) 11 (7.2) 14 (9.2) 0.677
Maculopathy (N [%]) 17 (11.1) 19 (12.4) 0.859
fSRT = fractionated stereotactic photon beam radiotherapy.
PBR = proton beam radiotherapy.
SD = standard deviation.
Table 4
The risk of a complication caused by treatment (fSRT or PBR; fSRT served as the
reference) in the matched study population. Presented as hazard ratio with
corresponding 95% CI*.
Matched study population (N = 306)
Recurrence 1.50 (0.42–5.32)
Neovascular glaucoma 0.50 (0.23–1.11)
Vitreous haemorrhage 0.19 (0.07–0.56)#
Optic neuropathy 1.67 (0.61–4.59)
Maculopathy 1.18 (0.53–2.64)
Enucleation 0.47 (0.19–1.15)
fSRT = fractionated stereotactic photon beam radiotherapy.
PBR = proton beam radiotherapy.
CI = confidence interval.
* = Adjusted for age, gender, TNM-classification, margin to the fovea, and margin to
the optic disc.
# = Significant values.
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26.5 months for PBR patients (IQR: 13.2–32.2 months). The actuar-
ial rates of neovascular glaucoma are presented in Table 2. After
developing neovascular glaucoma, enucleation was required in 4
and 13 patients after PBR and fSRT respectively.
More fSRT patients (18.3%) developed a VH than PBR patients
(3.3%) (p < 0.001) (Table 1). VH was not associated with tumour
characteristics for the total study population (Table 3). We found
that patients treated with fSRT had significant greater risk of VH
compared to PBR (HR 0.19; 95% CI 0.07–0.56) (Table 4). The median
time to develop a VH was 24.8 months for fSRT patients (IQR: 9.6–
33.4 months) and 11.6 months for PBR patients (IQR: 4.7–
35.0 months). Eleven of the 35 patients treated with fSRT had a
VH at baseline. Of those 11 patients, four VH resolved and seven
VH remained. After we excluded the seven fSRT patients with a
remaining VH from baseline, we found 28 VH that developed after
treatment (HR 0.25; 95% CI 0.08–0.75, p < 0.013). The actuarial
rates of VH are presented in Table 2.
Optic neuropathy developed in 7.2% and 9.2% of patients treated
with fSRT and PBR, respectively (p = 0.677) (Table 1). Tumours
extending within 3 mm of the optic disc were significantly associ-
ated with optic neuropathy (HR: 0.24, 95% CI 0.09–0.62) (Table 3).
There was no difference in the rate of optic neuropathy between
fSRT and PBR (Table 4). The median time to optic neuropathy
was 17.6 months in fSRT patients (IQR: 12.3–26.4 months) andTable 2














fSRT = fractionated stereotactic photon beam radiotherapy.
PBR = proton beam radiotherapy.
22118.8 months in PBR patients (IQR: 11.7–28.3 months). The actuar-
ial rates of optic neuropathy are presented in Table 2.
Maculopathy occurred in 11.1% and 12.4% of patients after fSRT
and PBR, respectively (Table 1). T2 and T3 tumours were 2.0 times
more likely to develop maculopathy compared to T1 tumours
(Table 3). There was no difference in the incidence of maculopathy
(Table 4). The median time to maculopathy was 24.3 months in
fSRT patients (IQR: 10.7–49.0 months) and 19.4 months in PBR
patients (IQR: 14.2–61.0 months). The actuarial rates of maculopa-
thy after fSRT and PBR are presented in Table 2.Discussion
To our knowledge, this is the first study to compare outcome of
fSRT with PBR as a treatment for UM. We found that high 5-year











Side effects of fSRT versus PBR in uveal melanomaradiotherapy treatment (i.e., after 96.1% in PBR patients and 96.1%
in fSRT patients). In a matched study population (N = 306), the
most common complications were maculopathy (12.4%) after
PBR and vitreous haemorrhage (18.3%) after fSRT (p < 0.001)
(Table 1 and 4). Maculopathy and enucleation were significantly
and neovascular glaucoma was nearly significant associated with
large tumour size. As expected, with tumour proximity to optic
disc more optic neuropathy was observed. Neovascular glaucoma
was associated with tumours located further than 3 mm of the
fovea.
A weakness of the study is that fSRT and PBR were performed in
different centres, which may not have measured baseline features
and outcomes in the same way. It would have been ideal if both
centres had randomised patients, however, neither centre had
access to both forms of radiotherapy. As in other retrospectiveFig. 1. Cumulative incidence analyses with log-rank test on treatment (i.e., fractionated
for each complication (i.e., recurrence [A], neovascular glaucoma [B], vitreous haemor
patients are denoted by vertical tick marks. The dashed lines around the curve represent
222studies, our study may have also suffered from bias caused by
missing data and loss of patients from follow-up. In order to com-
pare the different complications of both treatments we performed
analyses on matched data to have equal groups regarding: sex, age
and tumour characteristics (TNM-classification, tumour distances
to fovea and optic disc).
An excellent 5-year tumour control rate was achieved with
either treatment and was comparable to previous studies
[15,19,22,23]. When we analysed the matched population only
VH was significant more common after fSRT than after PBR
(Table 4). Of note, 11 of the 35 patients treated with fSRT already
had VH at baseline; however, this had no influence on the develop-
ment of new VH after treatment. PBR patients had no VH at base-
line, as good tumour visualization was needed to perform clip
surgery prior to PBR. We are unable to explain why VH was morestereotactic photon beam radiotherapy [fSRT] and proton beam radiotherapy [PBR])
rhage [C], optic neuropathy [D], maculopathy [E], and enucleation [F]). Censored
s the confidence intervals for the point estimates of the cumulative incidence curve.
Fig. 1 (continued)
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occurred by chance. In any case, this was not a serious complica-
tion as it could easily be treated with vitrectomy. Tumour necrosis,
proliferative radiation retinopathy and posterior vitreous detach-
ment have been suggested as a presumed aetiology for VH [24].
In our study we did not take into account the regression rate of
the tumour, which might reflect the amount of tumour necrosis
and might explain part of the VH. Proliferative radiation retinopa-
thy is not specifically observed within this group of patients.
Another study after plaque radiotherapy found underlying diabetic
retinopathy, closer tumour proximity to the disc, greater tumour
thickness, and break in the Bruch membrane as predictive factors
for a VH [24]. In our study we also did not record break of Bruch
membrane routinely and did not have complete data on diabetes
mellitus status; however, we did not find an effect of tumours clo-
ser to optic nerve or tumour thickness as risk factors for vitreous
haemorrhages (Table 3).
When considering complications of both treatments, we
observed that the largest tumour diameter is an important risk fac-
tor for adverse outcome. In our population larger tumours required
more often an enucleation. This is in contrast to Yazici et al. who
found no differences in enucleation rates between eyes with large
and small/medium tumours (p = 0.2) after stereotactic radio-
surgery and fSRT [9]. In another study large T3 and T4 tumours
treated with PBR, 19.5% of the tumours were enucleated, which
was higher than in our cohort [25].
We recorded neovascular glaucoma in 8.5% of the PBR-treated
patients and 17.6 % in fSRT patients. Most proton beam centres
have reported higher percentages of neovascular glaucoma rang-
ing from 12.7% to 47% of the patients [26,27]. FSRT centres report
for 24.5–42% neovascula glaucoma [7,22]. A point of attention is
that almost 60% of the current study population was in the era
before anti-vascular endothelial growth factor (VEGF) intravitreal
injections, which could explain the high percentage of neovascu-
lar glaucoma in both groups. And with the current treatment
options with anti-VEGF we may expect less neovascular glau-
coma, however, this has to be evaluated in a prospective study
[28].
A tumour within 3 mm of the optic nerve would result in a high
dose of radiation of the optic nerve and consequently would lead to
a decrease in visual acuity. Juxtapapillary UM are a risk factor for
developing optic neuropathy (Table 3). And for those tumours, per-
centages of optic neuropathy as high as 68% were observed [29]. In223tumours treated with fSRT optic neuropathy occurs in 61.5% of
patients [22]. In PBR treated eyes comparable and higher percent-
ages (14–68%) of optic neuropathy were found [19,30]. This is in
contrast with a study where more than half of their patients had
juxtapapillary T3 and T4 UM and only 8.3% developed optic neu-
ropathy [25]. In the end, however, there is no standardized defini-
tion of optic neuropathy resulting in different definitions used by
different studies.
Maculopathy is another vision threating complication after
radiation. In our population, 57.5% of the UM were closer than
3 mm to the fovea. Despite that, only 11.1% of the fSRT patients
and 12.4% of the PBR patients developed a maculopathy and this
was not related to the tumour distance to the fovea in the current
study. Interestingly, as also observed in other studies, maculopathy
occurred more often with an increase in the size of the tumour, his-
tory of diabetes mellitus and presence of preoperative subretinal
fluid [30,31]. Guyer et al. observed in 89% of the paramacular
tumours maculopathy after PBR [32]. After radiation, high doses
of VEGF are found in the eye [33]. The treatment of anti- VEGF
intravitreal injections seems to limit visual loss associated with
radiation maculopathy, although this was analysed after a different
form of radiation treatment with plaque therapy [28,34]. Shields
et al. observed a decrease in radiation maculopathy with preserva-
tion of visual acuity after prophylactic Bevacizumab every four
months [28].
An enucleation was performed more often in eyes with a larger
tumour. This might be explained by the fact that patients with
peripheral tumours often present rather late and may have conse-
quently a larger tumour [35]. The 5-year overall enucleation rate is
higher in patients treated with fSRT (12.4%) than in patients trea-
ted with PBR (5.9%). However, there is no significant difference
between treatments in the risk of enucleating the eye. When com-
paring different studies, it is important to keep in mind that the
indication of a treatment can differ, as fSRT cannot be performed
for small tumours whereas PBR can. In other centers where fSRT
is performed, the percentages of enucleation were 13.2–17%
[22,36]. The same counts for UM treated with PBR, where 7.7% of
the eyes were enucleated after 5 years [15].
As the local control in UM patients is high regardless of treat-
ment, the emphasis must lie on limiting the ocular morbidity for
patients’ quality of life [37]. Moreover, knowledge on the occur-
rence of complications can help caregivers to apply personalized
treatment.
Side effects of fSRT versus PBR in uveal melanomaIn summary, it can be stated that both treatment options are
comparable in their outcome, although fSRT patients developed
more vitreous haemorrhages. This is a complication that can be
managed very well surgically. As observed in other studies juxta-
papillary location has a higher risk of developing optic neuropathy,
irrespective of the type of radiation. Overall, in our population, the
risk factor for maculopathy and enucleation was the increase in
tumour size. A tumour located more than 3 mm from the fovea
is more prone to develop neovascular glaucoma.
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